Gamida Cell Ltd (GMDA)

Overview

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company dedicated to the development of innovative cell therapies aimed at curing blood cancers and serious blood diseases. Since its incorporation in 1998, Gamida Cell has been at the forefront of cell therapy research and development, leveraging its scientific expertise to create potentially life-saving treatments. Headquartered in Jerusalem, Israel, the company has made significant progress in the field, advancing its leading product candidates through rigorous clinical trials. The focus on research-driven results underscores Gamida Cell's commitment to meeting the urgent needs of patients suffering from complex hematologic conditions.

Products and Services

• Omidubicel

This lead product candidate from Gamida Cell represents a pioneering approach in cell therapy for the treatment of hematologic malignancies. Omidubicel has successfully completed Phase III clinical trials, demonstrating its potential as a transformative treatment option. Omidubicel is designed to enhance the success rates of bone marrow transplants, offering hope to patients with blood cancers seeking a curative outcome. Additionally, omidubicel is under investigation in Phase II clinical trials for its efficacy in treating severe aplastic anemia, a rare and serious blood disorder.

• GDA-201

An investigational cancer immunotherapy, GDA-201 utilizes Natural Killer (NK) cell-based therapy to target and eliminate cancer cells. Currently in Phase I/II studies, GDA-201 is being explored as a treatment for patients with relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. This innovative approach aims to harness the power of the body's own immune system to fight cancer, representing a new frontier in the therapeutic landscape for challenging hematologic cancers.